Introduction {#Sec1}
============

Early identification of tissue hypoperfusion and adequate resuscitation are key factors in the management of patients with shock \[[@CR1], [@CR2]\]. Although early resuscitation seems to improve outcomes in severe sepsis and septic shock, the relative value of resuscitation goals continues to be highly debated \[[@CR3]--[@CR6]\]. Monitoring of ScvO~2~ is widely recommended \[[@CR3]--[@CR7]\] although strongly challenged by others \[[@CR8], [@CR9]\]. In an early trial, Rivers et al. \[[@CR3]\] observed a significant decrease in mortality when they used a resuscitation bundle targeting ScvO~2~ \>70 %. Conversely, recent data failed to confirm any benefit with this approach \[[@CR10]\]. However, it should be noted that ScvO~2~ was normal or near normal at inclusion in a number of patients in these trials \[[@CR10]\] as it has frequently been reported on admissions to the intensive care unit in studies subsequent to the River's trial \[[@CR11]\]. Moreover, normalization of systemic hemodynamic and oxygen metabolism variables does not ensure an adequate tissue perfusion and does not prevent progression to multiorgan dysfunction and death \[[@CR12]\]. Lactate has also been proposed as a target for resuscitation therapy. In fact, not only baseline lactate level \[[@CR13]\] but also its evolution under the influence of therapy \[[@CR14]\] has been associated with clinical outcomes. Despite promising results observed in one trial \[[@CR15]\], no consistent advantages have been found for lactate-based resuscitation bundles over resuscitation guided by oxygen parameters \[[@CR15]--[@CR17]\]. Accordingly, additional markers of inadequate perfusion should be explored, especially when ScvO~2~ values are close to normal.

Recently, the venous-to-arterial carbon dioxide difference (Pv-aCO~2~) has been proposed as an alternative marker of tissue hypoperfusion \[[@CR18], [@CR19]\]. In fact, persistently high Pv-aCO~2~ predicts adverse clinical outcomes independently of oxygen-derived parameters and it could anticipate lactate variations \[[@CR20]\]. However, the Pv-aCO~2~ may be normal despite the presence of significant hypoperfusion in high cardiac output states such as septic shock, where high flows might prevent venous CO~2~ accumulation; or inversely, Pv-aCO~2~ can increase in the absence of hypoperfusion, in part due to the Haldane effect \[[@CR21]\]. Consequently, CO~2~ variations must be evaluated according to O~2~ changes. Indeed, CO~2~ production should not exceed O~2~ availability during aerobic metabolism. Thus, the ratio between the Pv-aCO~2~ and the arterial-to-venous oxygen content difference (Da-vO~2~), as a surrogate of the *V*CO~2~/*V*O~2~ ratio (i.e., the respiratory quotient), may identify patients at risk of anaerobic metabolism. Using this rationale, Mekontso-Dessap et al. \[[@CR22]\] demonstrated that a Pv-aCO~2~ to Da-vO~2~ ratio \>1.4 was superior to Pv-aCO~2~, SvO~2~, and Da-vO~2~ in predicting hyperlactatemia in a cohort of critically ill patients. Importantly, Pv-aCO~2~/Da-vO~2~ ratio variations are faster than lactate kinetics, which make it an attractive variable to monitor. However, CO~2~ partial pressure (PCO~2~) is not equivalent to CO~2~ content (CCO~2~), particularly when O~2~ saturation varies (Haldane effect). Thus, Cv-aCO~2~/Da-vO~2~ variations should better reflect variations in *V*O~2~ than Pv-aCO~2~/Da-vO~2~, especially when ScvO~2~ or SvO~2~ is low.

As the Cv-aCO~2~ to Da-vO~2~ ratio could reflect ongoing anaerobic metabolism, we hypothesized that an increased Cv-aCO~2~/Da-vO~2~ could be used to identify patients at risk of adverse outcomes during early stages of septic shock and that this variable could provide additional information when combined with lactate levels.

Materials and methods {#Sec2}
=====================

We conducted a prospective observational study in a 60-bed mixed ICU in a university-affiliated hospital. The Fundación Valle del Lili's ethical and biomedical research committee approved the current study (protocol number 710; approval number 093-2014). A written informed consent was waived because all measurements and procedures routinely followed the local protocols for the management of severe sepsis and septic shock and no new therapeutic interventions were performed. Our "rapid-response team" evaluated all patients with suspected septic shock at the emergency room and clinical wards. Resuscitation was immediately started and these patients were rapidly admitted to the ICU. Presence of infection was established using the Centers for Diseases Control and Prevention criteria \[[@CR23]\] and septic shock was defined according to the criteria of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference \[[@CR24]\]. Antibiotics were started within 1 h of diagnosis of sepsis. An arterial catheter was placed in the radial or femoral artery while a pulmonary artery catheter (PAC) was inserted via the jugular or subclavian vein when deemed appropriate according to clinical judgment and local indications for the use of hemodynamic monitoring. All patients with a new episode of septic shock and equipped with a PAC were included for the study. Patients with a previous episode of severe sepsis or septic shock within the last 3 months, younger than 18 years old, pregnant women, with limitations of care, with liver cirrhosis Child--Pugh C, or severe chronic obstructive pulmonary disease were excluded.

General management {#Sec3}
------------------

All patients followed an early quantitative resuscitation protocol adapted from the Surviving Sepsis Campaign \[[@CR7]\] in order to target (a) mean arterial pressure (MAP) ≥65 mmHg; (b) urine output ≥0.5 mL/kg/min; (c) SvO~2~ ≥65 %; (d) normalization of lactate levels. In the case of attaining the SvO~2~ goal but with persistently high lactate levels, additional efforts were performed to attain normalization of the latter. Pulse pressure variations were used to indicate fluid responsiveness whenever applicable. In other cases, filling pressures and clinical judgment were used. Fluid resuscitation was conducted by repeated fluid challenges with crystalloids and/or albumin 4 %. Hydroxyethyl starches (HES) were not used.

Norepinephrine was the first-choice vasopressor to maintain MAP goals. Vasopressin titrated to a maximum of 0.03 UI/min was allowed in order to raise MAP or to decrease norepinephrine dose but never as a single vasopressor. Titrated dobutamine up to 20 μg/kg/min was used when myocardial dysfunction was demonstrated or when SvO~2~ goals were not achieved despite adequate intravascular volume and MAP. Mechanical ventilation was provided (when needed) under light sedation (midazolam) and analgesia (fentanyl, morphine); tidal volume was limited to 6--8 mL/kg. Low dose hydrocortisone was indicated if vasopressor requirement did not decrease during the first 6 h of resuscitation despite ensuring adequate intravascular volume. Glycemic control was adjusted to maintain glucose levels \<150 mg/dL. Finally, stress ulcer and venous thrombosis prophylaxis were provided according to international recommendations \[[@CR7]\].

Study protocol {#Sec4}
--------------

Time 0 (T0) was stated at the PAC insertion. We recorded the total volume of fluids received and the time elapsed between the first episode of hypotension and T0. We performed complete hemodynamic measurements and drew blood samples for arterial and mixed-venous gases analysis (ABL 300, Radiometer Copenhagen, Denmark) and arterial lactate at T0, and 6 h (T6), around 12 h (T12), and 24 h (T24) after. Vasopressors and inotropic doses, respiratory parameters, and total fluids were also registered at each measurement time. Organ dysfunction at day 3 was evaluated using the Sequential Organ Failure Assessment (SOFA) score \[[@CR25]\]. We also calculated the ventilator-free days and survival at day 28.

Carbon dioxide and oxygen variables {#Sec5}
-----------------------------------

We calculated CO~2~ and O~2~ variables at T0, T6, T12, and T24, as follows:DO~2~ = CaO~2~ × CI*V*O~2~ = (CaO~2~ − CvO~2~) × CIERO~2~ = (CaO~2~ − CvO~2~)/CaO~2~CaO~2~ = (Hg × SaO~2~ × 1.34) + (PaO~2~ × 0.003)CvO~2~ = (Hg × SvO~2~ × 1.34) + (PvO~2~ × 0.003)Pv-aCO~2~ = PvCO~2~ − PaCO~2~Da-vO~2~ = CaO~2~ − CvO~2~

where CaO~2~ and CvO~2~ are the arterial and venous O~2~ content, PaO~2~ and PvO~2~ represent their arterial and venous partial pressures respectively, CI represents the cardiac index, and ERO~2~ represents the oxygen extraction ratio.
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Definitions of the four groups {#Sec6}
------------------------------

Considering that in aerobic conditions *V*CO~2~ should not exceed *V*O~2~, we considered a Cv-aCO~2~/Da-vO~2~ ratio \>1.0 as abnormal. Hence, we analyzed hemodynamic and oxygen metabolism parameters for four predetermined groups according to lactate levels and Cv-aCO~2~/Da-vO~2~ attained after the first 6 h of resuscitation: group 1, lactate ≥2.0 mmol/L and Cv-aCO~2~/Da-vO~2~ ratio \>1.0; group 2, lactate ≥2.0 mmol/L and Cv-aCO~2~/Da-vO~2~ ratio ≤1.0; group 3, lactate \<2.0 mmol/L and Cv-aCO~2~/Da-vO~2~ ratio \>1.0; and group 4, lactate \<2.0 mmol/L and Cv-aCO~2~/Da-vO~2~ ratio ≤1.0.

Statistics {#Sec7}
----------

After demonstrating a non-normal distribution of data with a Kolmogorov--Smirnoff test, we used a Kruskal--Wallis test to compare continuous variables with a Tukey--Kramer test for multiple comparisons among the predefined groups. *χ*^2^ test was used to compare discrete variables (or Fisher's exact test, when appropriate). Multiorgan dysfunction at day 3 was evaluated using the Sequential Organ Failure Assessment (SOFA) score \[[@CR25]\] for the predefined groups. Survival curves up to day 28 were estimated using the Kaplan--Meier method and log-rank (Mantel--Cox) test was used to estimate differences among the predefined groups.

In a further analysis, variables were introduced into a multivariate model if significantly associated with mortality at day 28 at the univariate analysis when a*p* value was \<0.2. General demographics, hemodynamics, vasopressor use, fluids, and blood gases parameters at T0 and T6 were used in the model, previously testing for collinearity. These analyses were also conducted in those patients attaining SvO~2~ ≥65 %. A Hosmer and Lemeshow test was used to assess the goodness of fit of the model. Receiver operating characteristic (ROC) curves for the original model (i.e., the "large model") and a second one excluding the Cv-aCO~2~/Da-vO~2~ ratio (i.e., the "short model") were constructed in order to test the added value of the Cv-aCO~2~/Da-vO~2~ ratio in predicting mortality at day 28. The ROC curves were compared using the method described by DeLong and colleagues \[[@CR28]\].

Additional logistic regression models including Pv-aCO~2~/Da-vO~2~ instead of Cv-aCO~2~/Da-vO~2~ and another one including simultaneously Pv-aCO~2~/Da-vO~2~ and Cv-aCO~2~/Da-vO~2~ were also conducted to explore its relationship with mortality at day 28.

Finally, we described the time-course for oxygen metabolism variables, Pv-aCO~2~/Da-vO~2~ and Cv-aCO~2~/Da-vO~2~ during the first 24 h for both survivors and non-survivors at day 28.

Data are presented as median (25--75th percentiles). Risk assessments are presented as risk ratios with 95 % confidence intervals. A *p* value ≤0.05 (two-tailed) was considered significant.

Results {#Sec8}
=======

Selection of patients is shown in the Fig. 1 of the Electronic Supplementary Material (ESM). A total of 135 patients were included in the study during a period of 18 months. Mortality at day 28 in this cohort was 42 % and ICU length of stay was 6 (2--10) days. The time from first hypotension episode to catheter insertion and blood sampling (i.e., T0) was 3.0 (2.5--4.0) h and the median amount of fluids received before T0 was 1,977 (1,200--2,800) mL.

After the first 6 h of resuscitation, 110 (81 %) patients achieved a MAP \>65 mmHg and 98 (73 %) a SvO~2~ \>65 %. However, 84 (62 %) patients still had an arterial lactate ≥2.0 mmol/L and 65 (48 %) had a Cv-aCO~2~/Da-vO~2~ ratio \>1.0. Accordingly, 42 patients were classified into group 1, 42 into group 2, 23 into group 3, and 28 into group 4. Patients in groups 1 and 2 had higher APACHE II scores and required higher vasopressor doses at T0 (Table [1](#Tab1){ref-type="table"}). No significant differences were found in demographic data or other hemodynamic variables at T0 (Table [1](#Tab1){ref-type="table"} and ESM Table 1). All hemodynamic, blood gases, oxygen parameters, and ventilator settings at both T0 and T6 are presented in the ESM Table 1. Patients from groups 1 and 2 had more acidosis at T0 and T6. Regarding the clinical outcomes, patients from group 1 evolved with higher SOFA scores (Kruskal--Wallis, *p* \< 0.001; post hoc test demonstrated significant differences among groups 1 vs. 3 and 1 vs. 4) (Fig. [1](#Fig1){ref-type="fig"}) and they also had the lowest survival rates at day 28 \[log rank (Mantel--Cox) = 31.39, *p* \< 0.0001\] (Fig. [2](#Fig2){ref-type="fig"}). Intriguingly, patients in groups 2 and 3 had similar SOFA scores and outcomes at day 28 (Table [2](#Tab2){ref-type="table"}). Furthermore, patients from group 1 had the lowest *V*O~2~ at T6 and T12 compared to all other groups, even though cardiac output, SvO~2~, and DO~2~ were not different (ESM Fig. 2).Table 1Patient characteristicsGroup 1 (*n* = 42)Group 2 (*n* = 42)Group 3 (*n* = 23)Group 4 (*n* = 28)*p*Lactate ≥2.0 mmol/L + Cv-aCO~2~/Da-vO~2~ ratio \>1.0Lactate ≥2.0 mmol/L + Cv-aCO~2~/Da-vO~2~ ratio ≤1.0Lactate \<2.0 mmol/L + Cv-aCO~2~/Da-vO~2~ ratio \>1.0Lactate \<2.0 mmol/L + Cv-aCO~2~/Da-vO~2~ ratio ≤1.0Age (years)68 (59--75)64 (54--74)64 (52--79)67 (51--76)0.62APACHE II25.0 (21.0--34.3)^\*\*^24.5 (19.0--29.0)21.0 (19.0--23.0)^\*\*^20.0 (18.0--26.0)\<0.001SOFA day 114.5 (10.0--16.3)^\*\*¶^13.0 (9.0--15.0)^‡^9.0 (8.0--11.0)^\*\*^7.5 (5.8--10.0)^‡¶^\<0.001Time between diagnosis to catheter insertion (T0)3.0 (2.4--4.0)3.0 (2.5--3.3)3.0 (2.0--4.0)3.0 (2.5--4.0)0.57Fluids received before catheter insertion2,100 (1,542--2,818)1,988 (1,178--3,000)1,600 (1,200--2,200)1,550 (900--2,700)0.32Temperature (°C)37.0 (36.1--37.7)37.0 (37.1--37.9)37.0 (36.4--37.7)37.4 (36.8--37.9)0.23Source of infection, *n* (%) Pneumonia1213880.48 Abdominal111259 Urinary8854 Soft tissue6621 No specific site5324 Other0012Culture positive, *n* (%)31 (73.8)32 (76.2)18 (78.3)23 (82.1)0.45Antibiotics given at T0, *n* (%)42 (100)40 (95.2)22 (95.7)28 (100)0.35Antibiotics adequate, *n* (%)42 (100)40 (95.2)22 (95.7)28 (100)0.35Steroids, *n* (%)36 (85.7)^\*\*¶^37 (88.1)^†^15 (65.2)^†^18 (64.3)^¶‡^0.02Vasopressin, *n* (%)20 (47.6)^\*\*¶^23 (54.8)^†^3 (13)^†^2 (7.1)^¶‡^\<0.001Red blood cell transfusion, *n* (%)12 (28.6)7 (16.7)4 (17.4)6 (21.4)0.23Fluids and vasoactive agents Fluids, mL (IQR 25--75)  T02,100 (1,542--2,818)1,988 (1,178--3,000)1,600 (1,200--2,200)1,550 (900--2,700)0.32  T63,896 (2,950--5,000)4,100 (2,826--6,119)^†^2,700 (2,150--4,400)^†^3,176 (2,100--4,450)0.02 Norepinephrine, μg/kg/min (IQR 25--75), *n*  T00.32 (0.19--0.54), 38^\*\*¶^0.34 (0.18--0.41), 390.15 (0.10--0.29), 21^\*\*^0.16 (0.07--0.23), 26^¶^\<0.001  T60.36 (0.19--0.62), 38^\*\*¶^0.35 (0.17--0.53), 39^†‡^0.13 (0.08--0.20), 22^\*\*†^0.12 (0.05--0.17), 24^¶‡^\<0.001 Dobutamine, μg/kg/min (IQR 25--75), *n*  T02.74 (1.38--9.0), 43.10 (2.22--8.70), 68.56 (5.13--12.00), 56.34 (5.23--10.45), 50.26  T65.30 (4.84--8.12), 124.90 (3.33--9.35), 96.10 (5.13--12.0), 55.95 (2.50--9.20), 60.72Data are presented as median (IQR, i.e., 25--75th percentiles) unless specified otherwise*SOFA* Sequential Organ Failure Assessment, *APACHE II* Acute Physiology and Chronic Health Evaluation II\**p* \< 0.05 for groups 1 vs. 2\*\**p* \< 0.05 for groups 1 vs. 3^¶^ *p* \< 0.05 for groups 1 vs. 4^†^ *p* \< 0.05 for groups 2 vs. 3^‡^ *p* \< 0.05 for groups 2 vs. 4^ξ^ *p* \< 0.05 for groups 3 vs. 4Fig. 1Sequential Organ Failure Assessment (SOFA) scores at day 3 for predefined groups. Data presented as median (percentiles). Patients were separated into four groups according to lactate and Cv-aCO~2~/Da-vO~2~ ratio measured after the first 6 h of resuscitation: group 1, lactate ≥2.0 mmol/L and Cv-aCO~2~/Da-vO~2~ ratio \>1.0; group 2, lactate ≥2.0 mmol/L and Cv-aCO~2~/Da-vO~2~ ratio ≤1.0; group 3, lactate \<2.0 mmol/L and Cv-aCO~2~/Da-vO~2~ ratio \>1.0; and group 4, lactate \<2.0 mmol/L and Cv-aCO~2~/Da-vO~2~ ratio ≤1.0. Kruskal--Wallis one-way ANOVA, *p* \< 0.001. \*\**p* \< 0.01 by Tukey--Kramer showing differences between groups 1 vs. 3 and 1 vs. 4Fig. 2Survival probabilities up to day 28 according to lactate and Cv-aCO~2~/Da-vO~2~ after 6 h of resuscitation. Log rank (Mantel--Cox) = 31.39, *p* \< 0.0001. Group 1, lactate ≥2.0 mmol/L and Cv-aCO~2~/Da-vO~2~ ratio \>1.0; group 2, lactate ≥2.0 mmol/L and Cv-aCO~2~/Da-vO~2~ ratio ≤1.0; group 3, lactate \<2.0 mmol/L and Cv-aCO~2~/Da-vO~2~ ratio \>1.0; and group 4, lactate \<2.0 mmol/L and Cv-aCO~2~/Da-vO~2~ ratio ≤1.0Table 2Clinical outcomesVariableGroup 1 (*n* = 42)Group 2 (*n* = 42)Group 3 (*n* = 23)Group 4 (*n* = 28)*p*SOFA day 114.5 (10.0--16.3)^\*\*¶^13.0 (9.0--15.0)^†^9.0 (8.0 --11.0)\*\*7.5 (5.8--10.0)^†¶^\<0.001SOFA day 311.0 (8.0--13.0)^\*\*¶^8.0 (5.0--11.3)^†^5.0 (3.0--9.0)\*\*3.5 (2.0--6.0)^†¶^\<0.001ICU length of stay, days7.0 (1.0--12.0)4.5 (2.0--10.0)6.0 (4.0--8.0)7.5 (3.0--12.5)0.44Ventilator-free days0 (0--12)^\*¶\*\*^20 (0--25)^‡†^24 (14--26)^‡^25 (20--28)^†^\<0.001Mortality observed/expected at day 28, *n* (% inside group)30 (71.4)/18 (42.9)^\*¶\*\*^17 (40.5)/18 (42.9)^†^9 (39.1)/10 (43.5)^ξ^2 (7.1)/12 (42.8)^¶†ξ^\<0.001Data are presented as median (25--75th percentiles) except for mortality. ICU length of stay is reported for both alive and dead patients*SOFA* Sequential Organ Failure Assessment,*ICU* intensive care unit\**p* \< 0.05 for groups 1 vs. 2\*\**p* \< 0.05 for groups 1 vs. 3^¶^ *p* \< 0.05 for groups 1 vs. 4^‡^ *p* \< 0.05 for groups 2 vs. 3^†^ *p* \< 0.05 for groups 2 vs. 4^ξ^ *p* \< 0.05 for groups 3 vs. 4

Multivariate logistic regression analysis at T0 demonstrated that Cv-aCO~2~/Da-vO~2~ was an independent predictor of mortality at day 28 (RR 3.85; 95 % CI 1.60--9.27). When analysis was performed using the same variables at T6, Cv-aCO~2~/Da-vO~2~ was again related to higher mortality at day 28 (RR 3.97; 95 % CI 1.54--10.24), in addition to lactate levels (RR 1.58; 95 % CI 1.13--2.22) (Table [3](#Tab3){ref-type="table"}). An additional multivariate analysis performed in patients attaining SvO~2~ \>65 % showed that lactate levels (RR 2.41; 95 % CI 1.22--4.76) and Cv-aCO~2~/Da-vO~2~ (RR 5.71; 95 % CI 1.20--27.19) remained predictors of mortality at day 28 (Table [3](#Tab3){ref-type="table"}). The area under ROC curves for models including or excluding the Cv-aCO~2~/Da-vO~2~ ratio (i.e., the "large" and "short" model, respectively) were significantly different (AUC~large~ 0.8542, 95 % CI 0.7797--0.9286 vs. AUC~short~ 0.7943, 95 % CI 0.7050--0.8836. LR test, *χ*^2^ 17.81, *p* \< 0.001; *C* statistic, *χ*^2^ 4.52, *p* = 0.03) (Fig. [3](#Fig3){ref-type="fig"}).Table 3Multivariate logistic regression for predictors of mortality at day 28T0T6T6 (for SvO~2~ ≥65 %)^a^RR95 % CI*p*RR95 % CI*p*RR95 % CI*p*Cv-aCO~2~/Da-vO~2~3.851.60--9.270.0033.971.54--10.240.0045.711.20--27.190.03Lactate, mmol/L1.190.98--1.440.091.581.13--2.220.0082.411.22--4.760.01VO~2~, mL/min/m^2^1.000.98--1.010.590.990.98--1.000.241.010.99--1.020.30DO~2~, mL/min/m^2^1.000.99--1.000.691.000.99--1.010.431.000.99--1.010.67SvO~2~,  %0.970.90--1.040.350.930.86--1.010.06CI, L/min/m^2^0.820.44--1.530.540.940.39--2.260.891.280.33--4.960.72APACHE II1.080.98--1.190.091.030.94--1.140.540.940.80--1.100.45Age, years1.030.99--1.060.141.020.98--1.060.381.100.99--1.210.06Time before T0, h0.620.36--1.040.070.720.41--1.270.260.630.29--1.400.25Gender0.450.16--1.270.130.770.24--2.450.660.150.03--0.990.05Fluids, mL1.000.99--1.010.841.001.00--1.010.931.000.99--1.000.81Norepinephrine, μg/kg/min1.780.23--13.940.580.410.06--2.890.370.250.01--7.560.42MAP, mmHg0.960.92--1.010.090.980.92--1.050.580.980.89--1.090.71*Cv*-*CO* ~2~/*Da*-*vO* ~2~ mixed venous-to-arterial carbon dioxide to arterial-venous oxygen content differences ratio, *DO* ~2~ oxygen delivery, *VO* ~2~ oxygen consumption, *SvO* ~2~ mixed-venous oxygen saturation, *CI* cardiac index, *APACHE* *II* Acute Physiology and Chronic Health Evaluation II, *MAP* mean arterial pressure^a^Analysis just for patients attaining SvO~2~ \>65 % at T6Fig. 3Receiver operating characteristics (ROC) curves for prediction of mortality at day 28 for models including or not Cv-aCO~2~/Da-vO~2~ ratio. The "large model" included Cv-aCO~2~/Da-vO~2~ + lactate levels. The "short model" included lactate levels but not Cv-aCO~2~/Da-vO~2~. Both models also included oxygen consumption (VO~2~), oxygen delivery (DO~2~), mixed-venous oxygen saturation (SvO~2~), cardiac index, APACHE II, age, time before T0, gender, fluids administered, norepinephrine dose, and mean arterial pressure. Likelihood ratio test, *χ* ^2^ = 17.81, *p* \< 0.001. Differences between AUCs, *C* statistic, *χ* ^2^ 4.52, *p* = 0.03

We also found significant differences in the time-course of Pv-aCO~2~, Pv-aCO~2~/Da-vO~2~, lactate levels, and Cv-aCO~2~/Da-vO~2~ during the first 24 h of resuscitation between survivors and non-survivors at day 28 (repeated measurements ANOVA, *p* \< 0.05) (ESM Figs. 3--5).

Discussion {#Sec9}
==========

We observed that persistent hyperlactatemia combined with a high Cv-aCO~2~/Da-vO~2~ was associated with the most severe organ dysfunction and worst clinical outcomes, while simultaneous normalization of lactate and Cv-aCO~2~/Da-vO~2~ ratio was associated with the best outcomes. Interestingly, patients attaining lactate levels \<2.0 mmol/L combined with Cv-aCO~2~/Da-vO~2~ \>1.0 had similar outcomes to patients with persistent hyperlactatemia and low Cv-aCO~2~/Da-vO~2~ ratio.

We hypothesized that a Cv-aCO~2~/Da-vO~2~ \>1.0 reflects anaerobic metabolism as *V*CO~2~ should not be higher than *V*O~2~ during aerobic conditions. Indeed, occurrence of a high *V*CO~2~/*V*O~2~ has been previously reported in experimental conditions, where lower reductions in *V*CO~2~ than in *V*O~2~ have been associated with other markers of tissue hypoxia, suggesting the involvement of a non-aerobic source of CO~2~ \[[@CR29], [@CR30]\]. Consequently, a Cv-aCO~2~/Da-vO~2~ ratio \>1.0 (as a surrogate of the *V*CO~2~/*V*O~2~ ratio) could identify an excess of CO~2~ generation probably due to anaerobic metabolism and this condition could be associated with more unfavorable clinical outcomes as we report in our study. Using a similar rationale, Mekontso-Dessap et al. \[[@CR22]\] tested the hypothesis that Pv-aCO~2~/Da-vO~2~ better detects anaerobic metabolism than other parameters derived from PAC measurements in critically ill patients. They found a significant agreement between Pv-aCO~2~/Da-vO~2~ and lactate levels. However, the agreement between Pv-aCO~2~/Da-vO~2~ and lactate levels should not necessarily be considered as representative of anaerobic metabolism since hyperlactatemia is not always of hypoxic origin \[[@CR31], [@CR32]\]. Interestingly, our data demonstrated that a high Cv-aCO~2~/Da-vO~2~ might be present with normal or high lactate levels suggesting that these variables evolve independently probably because lactate kinetics can be slower than Cv-aCO~2~/Da-vO~2~ variations. Thus, in the presence of hyperlactatemia a high Cv-aCO~2~/Da-vO~2~ may favor anaerobic metabolism as the possible source of lactate, while a normal Cv-aCO~2~/Da-vO~2~ may suggest that lactate accumulation is due to other causes \[[@CR33]--[@CR36]\].

Searching for other markers of ongoing tissue hypoxia could increase the information given by lactate levels during resuscitation of septic shock. Recently, Rimachi et al. \[[@CR37]\] reported the presence of hyperlactatemia in 65 % of patients with septic shock, but only 75 % of these patients exhibited increased lactate/pyruvate ratio, confirming that hyperlactatemia may be not due to hypoxia, especially during the early stages of shock. Consistent with that study, 71 % of the patients in our study had hyperlactatemia at T0 and half of them had an elevated Cv-aCO~2~/Da-vO~2~. Interestingly, hyperlactatemic patients evolving with a high Cv-aCO~2~/Da-vO~2~ at T6 (i.e., after initial resuscitation) had a lower *V*O~2~ compared with those evolving with normal Cv-aCO~2~/Da-vO~2~, despite similar DO~2~ values. This suggests that a high Cv-aCO~2~/Da-vO~2~ coupled with hyperlactatemia could identify ongoing *V*O~2~/DO~2~ dependence. In agreement with this concept, Monnet et al. \[[@CR38]\] recently reported that *V*O~2~ increased after fluid administration only in patients with a pre-fluid high Pv-aCO~2~/DavO~2~ ratio. In other words, a *V*CO~2~/*V*O~2~ ratio estimated by the Pv-aCO~2~/DavO~2~ or the Cv-aCO~2~/DavO~2~ could be used to predict fluid responsiveness at the tissue level.

Intriguingly, both Cv-aCO~2~/Da-vO~2~ and lactate levels were independent factors determining clinical outcomes, at T0 and T6. As expected, patients with combined increase in Cv-aCO~2~/Da-vO~2~ and lactate had the worse outcome, while patients with both variables normal had the best outcomes. Interestingly, patients attaining normal lactate levels at T6 but with a high Cv-aCO~2~/Da-vO~2~ had a similar incidence of multiorgan dysfunction and unfavorable clinical outcomes as hyperlactatemic patients with a Cv-aCO~2~/Da-vO~2~ ≤1.0. This further emphasizes the additive value of both indices.

Recent human studies suggest that Pv-aCO~2~ may identify persistent perfusion derangements in apparently resuscitated septic shock patients \[[@CR18], [@CR20], [@CR39]\]. The simplicity of Pv-aCO~2~ measurement makes it an attractive tool to guide resuscitation in the clinical setting. However, the Pv-aCO~2~ is a physiologically complex measurement, as the relationship between the CO~2~ partial pressure (PCO~2~) and the CO~2~ content (CCO~2~) is affected by O~2~ saturation, i.e., the Haldane effect \[[@CR21]\]. Accordingly, clinical interpretation of the Pv-aCO~2~ can be difficult since its increase can be observed in both aerobic and anaerobic conditions.

Another important question is whether Pv-aCO~2~/Da-vO~2~ can be used as a surrogate of Cv-aCO~2~/Da-vO~2~. This approach, used by several investigators \[[@CR22], [@CR38]\], assumes that CO~2~ partial pressure (PCO~2~) keeps a quasi-linear relationship with CO~2~ content (CCO~2~) over the physiological range of PCO~2~, i.e., along the steep portion of the CO~2~ dissociation curve. However, the relationship between PCO~2~ and CCO~2~ becomes non-linear if oxygen saturation, arterial-venous pH difference, and/or hemoglobin concentrations change. In this respect, several studies \[[@CR21], [@CR40]\] reported dissociation between CCO~2~ and PCO~2~ in the splanchnic region when CCO~2~ decreased in the venous splanchnic effluent while PCO~2~ paradoxically increased during increases of splanchnic blood flow. In fact, they showed that venous to arterial PCO~2~ differences could increase or decrease for identical blood flow increases. Thus, depending on the basal venous oxygen saturation, the Haldane effect may cause a decrease or increase in the respective venous to arterial PCO~2~ difference in response to the same changes in blood flow and metabolism \[[@CR40]\]. Thus, theoretically Cv-aCO~2~/Da-vO~2~ is not equivalent to Pv-aCO~2~/Da-vO~2~ especially during low PCO~2~ and SvO~2~ conditions. Importantly, despite the similarities in the time-course of the Pv-aCO~2~/Da-vO~2~ and the Cv-aCO~2~/Da-vO~2~ (ESM Figs. 3 and 4), we did not find significant association with day-28 mortality for the Pv-aCO~2~/Da-vO~2~ when it was included instead of Cv-aCO~2~/Da-vO~2~ in the logistic regression (ESM Table 2). An additional analysis simultaneously including the Pv-aCO~2~/Da-vO~2~ and the Cv-aCO~2~/Da-vO~2~ demonstrated that despite the former being significantly associated with mortality in the univariate analysis, it was not maintained in the multivariate analysis (ESM Table 3). Nevertheless, despite having ruled out mathematical collinearity between Pv-aCO~2~/Da-vO~2~ and Cv-aCO~2~/Da-vO~2~ in the model, it would be debatable to refuse that any collinearity might exist between two variables tightly related. However, we admit that Pv-aCO~2~/Da-vO~2~ could be equivalent to Cv-aCO~2~/Da-vO~2~ when PCO~2~, pH, and SvO~2~ approximate to normality, which occurs frequently. Cv-aCO~2~/DavO~2~ is an approximation of respiratory quotient, and thus it has a strong physiological meaning. Even though it is more complicated to compute, it is easier to interpret, with values above 1 suggesting anaerobic metabolism. Admittedly, computations of CO~2~ content and DavO~2~ are cumbersome and subject to an important risk of errors due to the number of variables included in the formulas. Nevertheless, our data suggest that the influence of measurement errors is limited as it correctly identified patients at increased risk of death.

Nowadays critically ill patients admitted to the ICU often exhibit normal or near-normal venous oxygen saturations \[[@CR11]\]. Interestingly, when we studied only the patients attaining SvO~2~ \>65 %, Cv-aCO~2~/Da-vO~2~ and lactate levels were still independent predictors of outcomes. Thus, Cv-aCO~2~/Da-vO~2~ could be a useful resuscitation variable in both low and normal SvO~2~ conditions.

We acknowledge some limitations of our study. First, both Cv-aCO~2~ and Da-vO~2~ are global variables and they may not represent regional or local perfusion derangements. Thus, tissue hypoperfusion inducing local CO~2~ accumulation may occur even when systemic venous CO~2~ remains normal. Second, the Cv-aCO~2~ may not increase during conditions of tissue hypoxia associated with high blood flow, even if CO~2~ production is increased due to anaerobic metabolism, as venous blood flow may be sufficient to wash out the CO~2~ generated by hypoxic cells \[[@CR41]\]. In these patients, the combination with lactate levels is useful to overcome this shortcoming. Finally, our observations were restricted to a relatively small sample of septic shock patients and although our results sound biologically plausible, they should be confirmed in future physiological studies to better understand the significance of the Cv-aCO~2~/Da-vO~2~ ratio during early stages of septic shock.

Conclusion {#Sec10}
==========

Combination of Cv-aCO~2~/Da-vO~2~ and lactate measurements at early stages of resuscitation can identify risk of adverse outcomes in septic shock. The Cv-aCO~2~/Da-vO~2~ ratio may become a potential resuscitation goal in patients with septic shock.
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**Take-home message:**The ratio between the Cv-aCO~2~ and the arterial-to-venous oxygen content difference (Da-vO~2~), as a surrogate of the *V*CO~2~/*V*O~2~ ratio (i.e., the respiratory quotient), may identify patients at risk of anaerobic metabolism.
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